Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer

Key Points

• To evaluate the pharmacokinetics of ribociclib across different ethnicities in breast cancer patients.
• Conducted a pharmacokinetic analysis comparing Asian and non-Asian patients.
• Reviewed dose recommendations for ribociclib in different ethnic groups.
• Ribociclib pharmacokinetics were comparable between Asian and non-Asian patients.
• Current dosing recommendations for Asian patients are supported by the findings.

Abstract